Bispecific antibodies structural design, production and purification strategies
Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders, and infections. Currently, there are 12 bispecific antibodies approved worldwide. .
Natural antibodies are monospecific, while bispecific antibodies recognize two different epitopes or antigens. This makes BsAbs hold great therapeutic promise for many diseases by linking an effector to a target cell, acting as ligands to two receptors or other mechanisms. However, translation of these concepts into treatments is challenging. Without proper engineering, the side products from the light chain mispairing, heavy chain mispairing and BsAb fragments could lead to low purity, inability of repetition and toxicity. To solve the technical problems, advanced design strategies have been investigated, such as Knobs-into-holes, CrossMab technology, Duobody, common light chain. These technologies have greatly improved the development of bispecific antibodies. And many people are trying the same designs to get their BsAb drugs. Do the designs always work well as reported? What should we take into consideration for BsAb design?
GenScript has production experience on thousands of BsAbs including about 80 BsAb formats. We know well how the design affects the production. This webinar will focus on various strategies for BsAb design, the side products, and how to get high purity BsAbs with different purification columns.
Most Popular Products
CRISPR Gene Editing
Antibodies
Protein Electrophoresis and Blotting
Molecular Biology
Stable Cell Lines
Cell Therapy
Diagnostics
Resources
